Fibrosis is central to multiple diseases as well as several life-threatening cancers such as hepatocellular carcinoma and cholangiocarcinoma.
- ALE-F02, CLDN1 mAb for Liver Fibrosis (F3/F4), with silenced effector function
- ALE-C04, CLDN1 mAb for Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma (CC), with an effector function targeting directly the cancer and at the same time the underlying fibrotic liver disease (dual effect on cancer and liver disease)
Alentis is using its portfolio of unique anti-CLDN1 monoclonal antibodies (mAbs) that binds to CLDN1 expressed on the cell membrane of liver myofibroblasts and the basolateral membrane of hepatocytes to develop a pipeline of novel mechanisms for fibrosis in late stage preclinical development:
Alentis aims to initiate clinical studies in 2021 for fibrosis and in 2022 for fibrosis-driven liver cancer, with Proof of Concept results expected by 2023 and 2024.
Alentis is widening its therapeutic reach to explore the potential of targeting CLDN1 in fibrosis of other tissues, including kidney where CLDN1 dysregulation is an established driver of the disease.
In addition, we are using our proprietary drug discovery platform for future pipeline expansion, pioneering a new approach to the screening and identification of novel targets, biomarkers and clinical candidates for advanced liver disease and cancer.